micro-community-banner
Profile Image
  • Saved
case study

 

Patient background

A 68-year-old man with a history of hypertension and type 2 diabetes presents with acute decompensated heart failure, reporting progressive dyspnea, two-pillow orthopnea, and bilateral lower extremity edema. He has a 5-year history of chronic heart failure with reduced ejection fraction (HFrEF) but has only been on loop diuretics for the past year, with no other components of guideline-directed medical therapy (GDMT) prescribed. His family history is notable for premature cardiovascular deaths in first-degree relatives.

Assessment and diagnosis 

On exam, the patient had diminished breath sounds, bilateral basal crackles, elevated jugular venous pressure, and pitting edema to the mid-shins. His oxygen saturation was 95% on room air. Echocardiogram revealed a reduced left ventricular ejection fraction (LVEF) of 25%, confirming HFrEF. Laboratory evaluation showed serum creatinine 1.4 mg/dL, eGFR 48 ml/min/1.73m², and potassium 4.2 mEq/L. Following treatment with intravenous loop diuretics, he achieved near-euvolemia and maintained a stable systolic BP of 115 mmHg without requiring inotropic support. Final diagnosis: acute on chronic HFrEF. Plans were made to initiate GDMT during hospitalization and to schedule outpatient follow-up for reassessment and titration.

  1. How do you initiate and optimize guideline-directed medical therapy in acute decompensated heart failure?
  2. How do you integrate newer agents like SGLT2 inhibitors into established GDMT sequencing in your practice?
Profile Image
  • Saved

Interatrial shunt implantation was safe in HF patients but showed benefit only in reduced LVEF, while worsening outcomes in preserved LVEF.

Profile Image
  • Saved
Consequences of Discontinuing Long-Term Drug Treatment in Patients With Heart Failure and Reduced Ejection Fraction - PubMed

Consequences of Discontinuing Long-Term Drug Treatment in Patients With Heart Failure and Reduced Ejection Fraction - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39453366/

There is uncertainty regarding the clinical effects of discontinuation of drugs for heart failure after long-term use. The withdrawal of long-term treatment can follow 1 of 4 distinct patterns: 1)...

Heart failure drug withdrawal often leads to clinical deterioration, with varied persistence of effects across agents. Evidence underscores avoiding treatment gaps and maintaining foundational therapies for optimal outcomes.

Profile Image
  • Saved
Cardiac Fibrosis in the Multi-Omics Era: Implications for Heart Failure - PubMed

Cardiac Fibrosis in the Multi-Omics Era: Implications for Heart Failure - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40146800/

Cardiac fibrosis, a hallmark of heart failure and various cardiomyopathies, represents a complex pathological process that has long challenged therapeutic intervention. High-throughput omics technologies have begun revolutionizing our understanding of...

Multi-omics technologies unravel genetic, epigenetic, transcriptomic, proteomic, and metabolic mechanisms of cardiac fibrosis, revealing fibroblast heterogeneity, biomarkers, and therapeutic targets, driving precision medicine and personalized strategies for heart failure and cardiomyopathies.

Profile Image
  • Saved
Heart failure, inflammation and exercise - PubMed

Heart failure, inflammation and exercise - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/40520009/

Heart failure (HF) is a condition characterized by high morbidity, mortality, and a substantial healthcare burden, in which inflammation plays a pivotal role. This review provides a comprehensive overview of...

This review highlights inflammation’s central role in heart failure progression, discussing immune alterations, biomarkers, and signaling pathways, while emphasizing exercise’s therapeutic potential through anti-inflammatory modulation and personalized intervention strategies.

Profile Image